IP Library › Granted Patent US 10,889,574
Granted Patent B2
US 10,889,574 · App. 16/557,180 · Granted Jan 12, 2021

Method for producing diphenylmethane derivative

Inventors: Hee-kyoon Yoon (Cheongju-si, KR); Se-Hwan Park (Yongin-si, KR); Ji-sung Yoon (Yongi-si, KR); Soongyu Choi (Yongin-si, KR); Hee Jeong Seo (Yongin-si, KR); Eun-Jung Park (Yongin-si, KR); Younggyu Kong (Yongin-si, KR); Kwang-Seop Song (Yongin-si, KR); Min Ju Kim (Yongin-si, KR); So Ok Park (Yongin-si, KR)
Assignees: DAEWOONG PHARMACEUTICAL CO., LTD.; GREEN CROSS CORPORATION
C07D409/04B01D9/005C07D307/78C07D407/04C07B51/00C07B2200/13Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,889,574
App. No.
16/557,180
Granted
Jan 12, 2021
Kind
B2
Abstract

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

Claims (64)

1. A method for producing a compound of the following Formula 1a, the method comprising the steps of:

(1) reacting a compound of the following Formula 2 with a compound of the following Formula 3 and subjecting the resultant to a cyclization reaction, to obtain a compound of the following Formula 4;

(2) subjecting the compound of Formula 4 to aldehydation or amidation, followed by reacting the resultant with a compound of the following Formula 5 and performing reduction, to obtain a compound of the following Formula 6; and

(3) reacting the compound of Formula 6 with a compound of the following Formula 7, and performing deprotection and reduction,

in the formulae,

A is oxygen (O);

n is 1 or 2;

PG is a protecting group;

X′ is halogen or C 1-7 alkyl;

X, Y, and Hal are each independently halogen;

B is (B-1)

in which Ra, Rb, Rc, and Rd are each independently hydrogen, halogen, hydroxy, mercapto, cyano, nitro, amino, carboxy, oxo, C 1-7 alkyl, C 1-7 alkylthio, C 2-7 alkenyl, C 2-7 alkynyl, C 1-7 alkoxy, C 1-7 alkoxy-C 1-7 alkyl, C 2-7 alkenyl-C 1-7 alkyloxy, C 2-7 alkynyl-C 1-7 alkyloxy, C 3-10 cycloalkyl, C 3-7 cycloalkylthio, C 5-10 cycloalkenyl, C 3-10 cycloalkyloxy, C 3-10 cycloalkyloxy-C 1-7 alkoxy, phenyl-C 1-7 alkyl, C 1-7 alkylthio-phenyl, phenyl-C 1-7 alkoxy, mono- or di-C 1-7 alkylamino, mono- or di-C 1-7 alkylamino-C 1-7 alkyl, C 1-7 alkanoyl, C 1-7 alkanoylamino, C 1-7 alkylcarbonyl, C 1-7 alkoxycarbonyl, carbarmoyl, mono- or di-C 1-7 alkyl carbamoyl, C 1-7 alkylsulfonylamino, phenylsulfonylamino, C 1-7 alkylsulfinyl, C 6-14 arylsulfanyl, C 6-14 arylsulfonyl, C 6-14 aryl, 5- to 13-membered heteroaryl, 5- to 10-membered heterocycloalkyl, 5- to 10-membered heterocycloalkyl-C 1-7 alkyl, or 5- to 10-membered heterocycloalkyl-C 1-7 alkoxy;

ring C is C 3-10 cycloalkyl, C 5-10 cycloalkenyl, C 6-14 aryl, 5- to 13-membered heteroaryl, or 5- to 10-membered heterocycloalkyl;

the alkyl, alkenyl, alkynyl, and alkoxy are each independently unsubstituted, or have one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C 1-7 alkyl, and C 2-7 alkynyl;

the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycloalkyl are each independently unsubstituted, or have one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C 1-4 alkyl, and C 1-4 alkoxy; and

the heteroaryl and heterocycloalkyl each independently contain one or more heteroatoms selected from the group consisting of N, S, and O.

2. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (1) includes the steps of:

(i) reacting the compound of Formula 2 with the compound of Formula 3 to obtain a compound of the following Formula 3a;

(ii) subjecting an allyl group of the compound of Formula 3a to a rearrangement reaction and subjecting the resultant to an oxidation or ozonation reaction followed by performing reduction, to obtain a compound of the following Formula 3d; and

(iii) subjecting the compound of Formula 3d to a cyclization reaction, to obtain the compound of Formula 4,

in the formulae, n, X, and Y are as defined in claim 1 .

3. The method for producing the compound of Formula 1a according to claim 2 ,

wherein the cyclization reaction is a cyclization reaction using a Vilsmeier reagent, a cyclization reaction using a leaving group, a cyclization reaction using a halide, or a cyclization reaction using a Mitsunobu reaction.

4. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (2) includes subjecting the compound of Formula 4 to aldehydation, to obtain a compound of the following Formula 4a, and then reacting the compound of Formula 4a with the compound of Formula 5,

in the formula, n, X, and Y are as defined in claim 1 .

5. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (2) includes subjecting the compound of Formula 4 to amidation, to obtain a compound of the following Formula 4b, and then reacting the compound of Formula 4b with the compound of Formula 5,

wherein n, X, and Y are as defined in claim 1 .

6. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the method further comprises an alkylation reaction after the step (3), and X′ is C 1-7 alkyl.

7. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (3) further includes isolating only a compound in which glucose is in a β-form, after or during the deprotection and reduction process.

8. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (3) is carried out by the method comprising the steps of:

(3a-1) reacting the compound of Formula 6 with the compound of Formula 7 in the presence of n-butyllithium, sec-butyllithium, t-butyllithium, or i-propylmagnesium chloride, to obtain a compound of the following Formula 7a;

(3a-2) subjecting the compound of Formula 7a to deprotection and methylation reactions under an acid condition in the presence of methanol, to obtain a compound of the following Formula 7d;

(3b) reducing the compound of Formula 7d to obtain a compound of the following Formula 7e; and

(3c) introducing a protecting group into the compound of Formula 7e, heating the resultant in alcohol, ethyl acetate, or dichloromethane, and isolating and deprotecting the resulting precipitate, to obtain only a β-form,

in the formulae, PG is a protecting group; and A, B, n, and X are as defined in claim 1 .

9. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (3) is carried out by a method comprising the steps of:

(3a′) reacting the compound of Formula 6 with the compound of Formula 7 in the presence of n-butyllithium, sec-butyllithium, t-butyllithium, or i-propylmagnesium chloride, and subjecting the resultant to deprotection and methylation reactions under an acid condition in the presence of methanol without a separate purification, to obtain a compound of the following Formula 7d;

(3b′) reducing the compound of Formula 7d to obtain a compound of the following Formula 7e; and

(3c′) introducing a protecting group into the compound of Formula 7e to isolate only a β-form, and performing deprotection,

in the formulae, A, B, n, and X are as defined in claim 1 .

10. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the step (3) is carried out by the method comprising the steps of:

(3a″) reacting the compound of Formula 6 with the compound of Formula 7 in the presence of n-butyllithium, sec-butyllithium, t-butyllithium, or i-propylmagnesium chloride, and subjecting the resultant to deprotection and methylation reactions under an acid condition in the presence of methanol without a separate purification, to obtain a compound of the following Formula 7d;

(3b″) introducing a protecting group into the compound of Formula 7d to obtain a compound of the following Formula 7f; and

(3c″) isolating only a β-form of the compound of Formula 7f and performing reduction, and then performing deprotection,

in the formulae, PG is a protecting group; and A, B, n, and X are as defined in claim 1 .

11. The method for producing the compound of Formula 1a according to claim 9 , wherein each of the compound of Formula 7 and n-butyllithium is used in an amount of 1.5 to 2.5 equivalents with respect to 1 equivalent of the compound of Formula 6.

12. The method for producing the compound of Formula 1a according to claim 1 ,

wherein the method further comprises a step of performing crystallization using a solvent selected from the group consisting of toluene, ethyl acetate, dichloromethane, a mixture of tetrahydrofuran and dichloromethane, and a mixture of tetrahydrofuran and n-hexane, after the step (3).

13. The method for producing the compound of Formula 1a according to claim 1 ,

wherein n is 1.

14. The method for producing the compound of Formula 1a according to claim 1 ,

wherein A is oxygen;

n is 1;

X′ is halogen; and

B is phenyl which is unsubstituted or substituted with one or two substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, mercapto, C 1-7 alkyl, C 3-10 cycloalkyl, and C 1-7 alkoxy.

15. The method for producing the compound of Formula 1a according to claim 10 , wherein each of the compound of Formula 7 and n-butyllithium is used in an amount of 1.5 to 2.5 equivalents with respect to 1 equivalent of the compound of Formula 6.

Assignments (1)
LICENSE Recorded Nov 16, 2022
From: GREEN CROSS CORPORATION
To: DAEWOONG PHARMACEUTICAL CO., LTD.
Reel/Frame 061795/0506 →
Priority Claims (1)
KR 10-2016-0075910 · Jun 17, 2016 · national
Continuity (2)
Division 16310005
Related Publication 20190382390A1 · Dec 19, 2019
Cited By (1)
US 12,497,390